For Research Use Only

## P27; KIP1 Monoclonal antibody

Catalog Number:67355-1-lg 3 Publications




Basic Information	Catalog Number: 67355-1-lg	GenBank Accession Num BC001971		n Method: purification	
	Size:	GenelD (NCBI):	CloneNo.:	Junication	
	150ul , Concentration: 1600 ug/ml by		3F12C10		
	Nanodrop and 1000 ug/ml by Bradfor		-	Recommended Dilutions:	
	method using BSA as the standard;	P46527	WB 1:5000		
	Source:	Full Name:			
	Mouse Isotype: IgG1 Immunogen Catalog Number: AG14634	cyclin-dependent kinase inhibitor 1B (p27, Kip1)			
					Calculated MW:
		198 aa, 22 kDa			
		Observed MW: 27 kDa			
		Applications	Tested Applications:	Positive Controls:	
WB, ELISA	WB, ELISA WB : Jurkat		cells, K-562 cells, HSC-T6 cells, NIH/3T3		
Cited Applications: WB	cells				
Species Specificity:					
Human, mouse, rat					
Cited Species:					
	human, mouse	a cyclin-dependent kinase	a inhihitor which shares	a limited similarity with	
Background Information	human, mouse DKN1B, also named as P27 or KIP1, is CDK inhibitor CDKN1A/p21. P27 bind: and thus controlling cell cycle progres dependent phosphorylation and subs from quiescence to the proliferative s malignancies, including lung cancer, gastric cancer.	s to and prevents the activ ssion at G1. The degradation equent ubiquitination by S tate. Downregulation of P	ation of cyclin E-CDK2 o on of this protein, which SCF complexes, is requir 27 has been implicated	r cyclin D-CDK4 complexes is triggered by its CDK red for the cellular transition in the progression of severa	
	DKN1B, also named as P27 or KIP1, is CDK inhibitor CDKN1A/p21. P27 binds and thus controlling cell cycle progres dependent phosphorylation and subso from quiescence to the proliferative s malignancies, including lung cancer, gastric cancer.	s to and prevents the activ ssion at G1. The degradation equent ubiquitination by S tate. Downregulation of P hepatocellular carcinoma,	ation of cyclin E-CDK2 o on of this protein, which SCF complexes, is requir 27 has been implicated	r cyclin D-CDK4 complexes, is triggered by its CDK red for the cellular transition in the progression of severa uamous cell carcinomas, ar	
	DKN1B, also named as P27 or KIP1, is CDK inhibitor CDKN1A/p21. P27 binds and thus controlling cell cycle progres dependent phosphorylation and subso from quiescence to the proliferative s malignancies, including lung cancer, gastric cancer.	s to and prevents the activ ssion at G1. The degradation equent ubiquitination by S tate. Downregulation of P hepatocellular carcinoma, med ID Journal	ation of cyclin E-CDK2 o on of this protein, which SCF complexes, is requir 27 has been implicated , salivary cancer, oral sq	r cyclin D-CDK4 complexes, is triggered by its CDK ed for the cellular transition in the progression of severa uamous cell carcinomas, ar Application	
	DKN1B, also named as P27 or KIP1, is CDK inhibitor CDKN1A/p21. P27 bind: and thus controlling cell cycle progres dependent phosphorylation and subsi- from quiescence to the proliferative s malignancies, including lung cancer, gastric cancer. Author Pub Xin Zhou 347	s to and prevents the activities on at G1. The degradation of P2 state. Downregulation of P2 state. Downregulation of P2 shepatocellular carcinoma, med ID Journal 165572 J Hepatocel	ation of cyclin E-CDK2 o on of this protein, which SCF complexes, is requir 27 has been implicated	r cyclin D-CDK4 complexes, is triggered by its CDK red for the cellular transition in the progression of severa uamous cell carcinomas, ar Application WB	
	DKN1B, also named as P27 or KIP1, is CDK inhibitor CDKN1A/p21. P27 binds and thus controlling cell cycle progress dependent phosphorylation and subso from quiescence to the proliferative s malignancies, including lung cancer, gastric cancer. Author Pub Xin Zhou 347 Tongguan Tian 379	st to and prevents the activitistic activities and G1. The degradation of P. State. Downregulation of P. State. Downregulating the p. State. Downregulation of P. State	ation of cyclin E-CDK2 o on of this protein, which GCF complexes, is requir 27 has been implicated , salivary cancer, oral sq cell Carcinoma	r cyclin D-CDK4 complexes, is triggered by its CDK ed for the cellular transition in the progression of severa uamous cell carcinomas, ar Application WB WB	
	DKN1B, also named as P27 or KIP1, is CDK inhibitor CDKN1A/p21. P27 binds and thus controlling cell cycle progress dependent phosphorylation and subso from quiescence to the proliferative s malignancies, including lung cancer, gastric cancer. Author Pub Xin Zhou 347 Tongguan Tian 379	s to and prevents the activities on at G1. The degradation of P2 state. Downregulation of P2 state. Downregulation of P2 shepatocellular carcinoma, med ID Journal 165572 J Hepatocel	ation of cyclin E-CDK2 o on of this protein, which GCF complexes, is requir 27 has been implicated , salivary cancer, oral sq cell Carcinoma	r cyclin D-CDK4 complexes is triggered by its CDK red for the cellular transition in the progression of severa uamous cell carcinomas, ar Application WB	
Notable Publications	DKN1B, also named as P27 or KIP1, is CDK inhibitor CDKN1A/p21. P27 bind: and thus controlling cell cycle progres dependent phosphorylation and subsi- from quiescence to the proliferative s malignancies, including lung cancer, gastric cancer. Author Pub Xin Zhou 347 Tongguan Tian 379 Wei Chang 376 Storage: Store at -20°C. Storage Buffer:	s to and prevents the activi- ssion at G1. The degradation equent ubiquitination by State. Downregulation of P2 hepatocellular carcinoma, med ID Journal 65572 J Hepaton 38970 Cell Rep 43584 J Vasc Re	ation of cyclin E-CDK2 o on of this protein, which GCF complexes, is requir 27 has been implicated , salivary cancer, oral sq cell Carcinoma	r cyclin D-CDK4 complexes is triggered by its CDK red for the cellular transition in the progression of severa uamous cell carcinomas, ar Application WB WB	
Notable Publications	DKN1B, also named as P27 or KIP1, is CDK inhibitor CDKN1A/p21. P27 bind: and thus controlling cell cycle progres dependent phosphorylation and subso from quiescence to the proliferative s malignancies, including lung cancer, gastric cancer. Author Pub Xin Zhou 347 Tongguan Tian 379 Wei Chang 376 Storage: Storage Suffer: PBS with 0.02% sodium azide and 50°	s to and prevents the activi- ssion at G1. The degradation equent ubiquitination by S tate. Downregulation of P2 hepatocellular carcinoma, med ID Journal (65572 J Hepator (38970 Cell Rep (43584 J Vasc Rep (43584 J Vasc Rep)	ation of cyclin E-CDK2 o on of this protein, which GCF complexes, is requir 27 has been implicated , salivary cancer, oral sq cell Carcinoma	r cyclin D-CDK4 complexes, is triggered by its CDK ed for the cellular transition in the progression of severa uamous cell carcinomas, ar Application WB WB	
Background Information Notable Publications Storage	DKN1B, also named as P27 or KIP1, is CDK inhibitor CDKN1A/p21. P27 bind: and thus controlling cell cycle progres dependent phosphorylation and subsi- from quiescence to the proliferative s malignancies, including lung cancer, gastric cancer. Author Pub Xin Zhou 347 Tongguan Tian 379 Wei Chang 376 Storage: Store at -20°C. Storage Buffer:	s to and prevents the activi- ssion at G1. The degradation equent ubiquitination by S tate. Downregulation of P2 hepatocellular carcinoma, med ID Journal (65572 J Hepator (38970 Cell Rep (43584 J Vasc Rep (43584 J Vasc Rep)	ation of cyclin E-CDK2 o on of this protein, which GCF complexes, is requir 27 has been implicated , salivary cancer, oral sq cell Carcinoma	r cyclin D-CDK4 complexes is triggered by its CDK ed for the cellular transitio in the progression of severa uamous cell carcinomas, ar Application WB WB	

For technical support and original validation data for this product please contact:T: 1 (888) 4PTGLAB (1-888-478-4522) (toll freeE: proteintech@ptglab.comin USA), or 1(312) 455-8498 (outside USA)W: ptglab.com

This product is exclusively available under Proteintech Group brand and is not available to purchase from any other manufacturer.

## Selected Validation Data



Jurkat cells were subjected to SDS PAGE followed by western blot with 67355-1-1g (P27; KIP1 antibody) at dilution of 1:10000 incubated at room temperature for 1.5 hours.